Immunotherapy for metastatic renal cell carcinoma: Is it a therapeutic option yet?

Annals of Oncology

Volumn 18, Issue SUPPL. 6, 2007, Pages

  Guida, Mic ^a   Colucci, G ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Chemoimmunotherapy; Metastatic renal cell carcinoma; Vaccine

Indexed keywords

ALPHA INTERFERON; ALUMINUM POTASSIUM SULFATE; ANTINEOPLASTIC AGENT; BCG VACCINE; CANCER VACCINE; CYTOKINE; DENDRITIC CELL VACCINE; FLUOROURACIL; FREUND ADJUVANT; GAMMA INTERFERON; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; ISOTRETINOIN; MONOCLONAL ANTIBODY; NAVELBINE; QS 21; VINBLASTINE;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FOLLOW UP; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOSTIMULATION; KIDNEY CARCINOMA; LOW DRUG DOSE; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY TUMOR; METASTASIS; METHODOLOGY; PATHOLOGY; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS;

EID: 35748942010     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm245     Document Type: Conference Paper

References (25)

1. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
2. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
3. Yang JC, Childs R. Immunotherapy for renal cell cancer. J Clin Oncol 2006; 24: 5576-5583.
4. Parton M, Gore M, Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 5584-5592.
5. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889-897.
6. Dilman RO, Church D, Oldham RK et al. Inpatient continuous-infusion of interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 1993; 71: 2358-2370.
7. Atzpodien MJ, Korfen A, Franks CR et al. Home therapy with recombinant interleukin-2 and interferon-2b in advanced human malignancies. Lancet 1990; 335: 1509-1512.
8. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21(16): 3127-3132.
9. Mc Dermott DF, Regan MM, Clark JI et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interluekin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133-141.
10. Fossa SD, Martinelli G, Otto U et al. Recombinant interferon alpha-2a with or without vinblastine in metastatic renal cell carcinoma: Result of a European multicenter phase III study. Ann Oncol 1992; 3: 301-305.
11. Motzer RJ, Berg W, Ginsberg M et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2002; 20(1): 302-306.
12. Atzpodien J, Kirchner H, Bergmann L et al. Interleukin-2 and interferon Alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004; 22: 1188-1194.
13. Guida M, Latorre A, Selvaggi FP et al. Subcutaneous rIL-2 plus alpha interferon and vinblastine in metastatic renal cell carcinoma: A phase II study. Int J Oncol 1996; 10: 487-491.
14. Rohde D, Hayn HK, Blatter J et al. The efficacy of 2′,2′-difluorodeoxycytidine (gemcitabine) combined with interferon in human renal cell carcinoma cell lines. Int J Oncol 1998; 12(6): 1361-1366.
15. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: Implications for combination chemo-immunotherapy. Cancer Res 2002; 62: 2353-2358.
16. De Mulder PH, Weissbach L, Jakse G et al. Gemcitabine: A phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 1996; 37(5): 491-495.
17. Rini BI, Vogelzang NJ, Dumas MG et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 2000; 18(12): 2419-2426.
18. Rohde D, Thiemann D, Wildberger J et al. Treatment of renal cancer patients with gemcitabine (2′,2′-difluorodeoxycytidine) and interferons: Antitumor activity and toxicity. Oncol Rep 1998; 5(6): 1555-1560.
19. Ryan CW, Vogelzang NJ, Stadler WM. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. Cancer 2002; 94(10): 2602-2609.
20. Neri B, Doni L, Gemelli MT et al. Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer. J Urol 2002; 168(3): 956-958.
21. Guida M, Lorusso V, De Lena M et al. Subcutaneous rlL-2 plus vinorelbine (VNB) and gemcitabine (GEM) in metastatic renal cell carcinoma. Annual Meeting of American Society of Clinical Oncology (ASCO) 2002.
22. Nanus DM, Garino A, Milowsky MI et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004; 101(7): 1545-1551.
23. Porta C, Zimatore M, Imarisio I et al. Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: Final results of a single-institution Phase II study. Cancer 2004; 100(10): 2132-2138.
24. Parmiani G, Pilla L, Castelli C, Rivoltini. Vaccination of patients with solid tumors. Ann Oncoll 2003; 14(6): 817-824.
25. Whiteside TL, Odoux C. Dendritic cell biology and cancer therapy. Cancer Immunol Immunother 2004; 53(3): 240-248.